Brief: Galmed Reports Results From The Open-Label Part Of The Armor Study Showing Improvements In Histology, Imaging, And Biomarkers With Aramchol

Eocene

04/01/2023 13:23

Jan 4 (Reuters) - Galmed Pharmaceuticals Ltd  GLMD.O :
    * GALMED REPORTS RESULTS FROM THE OPEN-LABEL PART OF THE
ARMOR
STUDY SHOWING IMPROVEMENTS IN HISTOLOGY, IMAGING, AND BIOMARKERS
WITH ARAMCHOL
    * SUBMITTING DATA TO FDA TO START DISCUSSION ON
INCORPORATING MORE
SENSITIVE HISTOLOGY READING METHODOLOGIES AS PRIMARY ENDPOINTS
IN NASH STUDIES
    * ACTIVELY LOOKING FOR PARTNERING OPPORTUNITIES TO CONTINUE
ARAMCHOL'S CLINICAL DEVELOPMENT

Source text for Eikon:  ID:nPn3vSVc0a 
Further company coverage:  GLMD.O 
 ((Reuters.Briefs@thomsonreuters.com))